| 000 | 01084 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516064249.0 | ||
| 264 | 0 | _c20120118 | |
| 008 | 201201s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(11)61540-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLogothetis, Christopher J | |
| 245 | 0 | 0 |
_aTreatment of prostate cancer metastases: more than semantics. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJan 2012 |
||
| 300 |
_a4-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aBone Neoplasms _xsecondary |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOrchiectomy |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aRANK Ligand _xadministration & dosage |
| 773 | 0 |
_tLancet (London, England) _gvol. 379 _gno. 9810 _gp. 4-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(11)61540-7 _zAvailable from publisher's website |
| 999 |
_c21320752 _d21320752 |
||